D. Shcheblyakov

Comparison of different technologies for producing recombinant adeno-associated virus on a laboratory scale

D. V. Byrikhina, I. Esmagambetov, E. I. Ryabova, 2021, BIOpreparations. Prevention, Diagnosis, Treatment.

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

A. Shchetinin, V. Gushchin, O. Voronina, 2021, Vaccines.

Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection

O. Voronina, M. Kunda, N. Ryzhova, 2021, Acta naturae.

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern

O. Voronina, M. Kunda, N. Ryzhova, 2021, bioRxiv.

Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection

D. Logunov, O. Popova, M. Shmarov, 2022, Viruses.

[The use of monoclonal antibodies for the treatment of Ebola virus disease.]

T. E. Sizikova, V. Lebedev, G. V. Borisevich, 2018, Voprosy virusologii.